Clinical Conversations Exchange: A PCP-Obesity Specialist Collaboration Discussing the Most Undertreated Chronic Disease: Evidence-based Obesity Management
Following the posting of this activity tirzepatide has received FDA approval for use in adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
Jay Shubrook, DO, FACOFP, FAAFP
Professor Primary Care Department
Touro University California
College of Osteopathic Medicine
Fatima Cody Stanford, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS
Associate Professor of Medicine and Pediatrics
Obesity Medicine Physician-Scientist
Massachusetts General Hospital
Harvard Medical School
This enduring activity is an interactive exchange program with educational tools designed to help primary care providers use evidence-based strategies to manage obesity. The programming has been designed to help PCPs analyze the metabolic and hormonal pathways involved in the pathophysiology of obesity; select diagnostic strategies and interventions for obesity using guidelines and clinical data; distinguish between anti-obesity medications based on their safety, efficacy and mechanisms of action; and develop individualized treatment plans for patients with obesity using a shared decision-making approach. The instructional design is intended to facilitate a continuous networking exchange between obesity specialists and primary care providers that will enhance primary care physicians’ ability to manage patients with obesity, share knowledge, and create a higher level of confidence and ownership in treatment plans.
This educational activity is intended for U.S. primary care physicians, nurses, NPs, PAs, dieticians and RDs who manage patients with obesity.
Upon the completion of this program, attendees should be able to:
- Analyze the metabolic and hormonal pathways involved in the pathophysiology of obesity
- Select diagnostic strategies and interventions for obesity using guidelines and clinical data
- Distinguish between anti-obesity medications based on their safety, efficacy and mechanisms of action
- Develop individualized treatment plans for patients with obesity using a shared decision-making approach
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
COMMISION ON DIETETIC REGISTRATION
This program has received prior approval with the Commission on Dietetic Registration for dietitians and RDs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|Jay Shubrook, DO||Discloses that he has received consulting fees from Abbott, Bayer, and Novo Nordisk. He has also received fees for non-CME/CE services from Sanofi. He is also on the Advisory board for Abbott, Astra Zeneca, Bayer, Eli Lilly, Nervo, and Novo Nordisk.|
|Fatima Cody Stanford, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS||Discloses that she has received consulting fees from Novo Nordisk, Boehringer Ingelheim, Pfizer, Currax, Eli Lilly, Rhythm, Gelesis, Coral Health, Calibrate, Veri, LifeForce, Sweetch, GoodRX.|
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Cindy Lampner, MSLIS, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete pre-and-post surveys and evaluation
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.